ABL Bio: Eli Lilly will pay $40 million for licensing, research, and collaboration; and make an equity investment of $15 million. Collaborated with Eli Lilly to conduct joint research based on the bispecific antibody platform “Grabody”.

ABL Bio: Eli Lilly will pay $40 million for licensing, research, and collaboration; and make an equity investment of $15 million. Collaborated with Eli Lilly to conduct joint research based on the bispecific antibody platform “Grabody”.